NCT02377947

A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 50 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a retrospective study in adult patients with cirrhosis and grade 3 or 4 HE (West Haven Criteria) to evaluate the effectiveness and safety of lactulose retention enema in the treatment of deep grade HE (West Haven Criteria). The study will be conducted retrospectively in a multi center of a multispecialty tertiary care hospital in India, in which lactulose retention enema is the mainstay of management of cirrhotic patients with grade 3 or 4 HE (West Haven criteria). Dosing of lactulose retention enema in this study will be done according to the dosing described for rectal administration of lactulose (India): 300ml of lactulose mixed with 700ml of potable water to be used as a retention enema; the enema is to be retained for 30-60 minutes and repeated every 4-6 hours until the patient is able to take oral medication. This treatment regime is also the standard protocol of management of deep grade HE (West Haven criteria) in the study centers. The standard treatment protocol of deep grade HE (West Haven criteria) of the study centers will also ensure that all known contraindications of lactulose will be respected before administration of lactulose retention enema to the study patients. The retrospective hospital records of the patient population of interest within the past 6 months will be identified, and these records will be used to collect data required for analysis.

Detailed description

Data to be collected: Data that would be collected for the study as part of retrospective chart review: 1. Patient demographics: age, gender, weight 2. Medical history 3. Etiology of cirrhosis (alcohol abuse, hepatitis, autoimmune, cryptogenic, other) 4. Diagnosis of cirrhosis 5. History of previous HE (if yes, the number of episodes in the past) 6. Grade of HE (as per the West-Haven criteria) at admission, 24 hrs and 48 hours post treatment with lactulose 7. Precipitating factor(s) of HE (Dehydration, GI bleeding, protein overload, constipation, infection, others) 8. Dose and duration of lactulose enema 9. Treatment given for precipitating factors 10. Laboratory data on haemoglobin, platelet, bilirubin, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine, sodium, potassium, and blood ammonia 11. Complete reversal of deep-grade HE (\< Grade 2 as per West-Haven criteria) (yes/no) 12. Time to complete reversal of deep-grade HE 13. Number of days in hospital 14. Adverse drug reaction experienced by the patient 15. Complications experienced by the patient 16. Other pharmacovigilance relevant information (OPRI)

Conditions

• Hepatic Encephalopathy

Timeline

• Start date: 2015-12-01
• Primary completion: 2016-03-01
• Completion: 2016-03-01
• First posted: 2015-03-04
• Last updated: 2020-02-10
• Results posted: 2020-02-10

Locations

3 sites across 1 country: India